The RNA-Based Therapeutics Market Size was valued at USD 13.1 Billion in 2022 and is projected to grow from USD 13.9 Billion in 2023 to USD 22.32 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.10% during the forecast period (2024 - 2032). The increasing amount of money being spent on nucleic acid treatments and the rise in hereditary illnesses including cancer, sickle cell anemia, and cystic fibrosis are the key market drivers boosting the expansion of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Market CAGR for RNA-Based Therapeutics is being driven by the rowing alliances and cooperation between industry participants. While antisense science makes an RNA strand from a known gene sequence, RNAi technology works by eliminating specific mRNA molecules. After attaching to mRNA, these freshly created RNA strands render mRNA dormant. The key factor propelling this market's growth is the possibility for RNA-based therapies to silence genes. Additional motivators include the target precision and selectivity of RNA interference (RNAi) treatments, a stronger emphasis on products as opposed to platform technologies, and virtual drug manufacturing models that allow businesses to lower the cost of research.
Additionally, The fast expanding field of RNA therapies has the potential to completely transform how many diseases are treated. Strategic alliances and partnerships between RNA technology makers and market participants have propelled the market's explosive expansion. RNA therapies are developed and commercialized more quickly when market participants collaborate and form partnerships. By pooling their resources and skills, corporations can share the costs and risks of developing medicines and gain access to novel innovations and markets. There are a number of reasons why products are discontinued or recalled, such as unanticipated negative consequences, safety concerns, problems with efficacy, or noncompliance with regulations.
Single-stranded nucleic acid molecules known as RNA aptamers have a high affinity and selectivity for certain targets. Numerous therapeutic uses, such as those for infectious disorders, heart conditions, and cancer, have been studied. One significant area of market opportunity is the advancement in the creation of medicines based on RNA aptamers. This is due to the several possible benefits that RNA aptamers offer over conventional medication therapy. The development of RNA aptamer-based medicines has significantly changed the field of RNA therapeutics. As of right now, pipeline products outnumber authorized items. One such example involves pegaptanib sodium (Macugen), discovered by Nexstar Pharmaceuticals, which is an anti-vascular endothelial growth factor (anti-VEGF) RNA aptamer to treat all kinds of neovascular age-related macular degeneration.
For instance, a report in MDPI states that more than 400 RNA-targeting drug research initiatives were underway worldwide in August 2022; of these, two-thirds are in the pre-IND (pre-investigational new drug) stage, one-third are in Phase I or II early clinical trials, roughly 3% are in Phase III, and some are waiting for approval from regulators for COVID-19 treatment. Thus, result in driving the RNA-Based Therapeutics market revenue.
The RNA-Based Therapeutics Market segmentation, based on type includes RNA interference (RNAi) and RNA antisense. The RNA antisense segment dominated the market. This is due to the fact that RNA antisense technology has applications in neurological illnesses, cancer, and uncommon genetic abnormalities, among other therapeutic domains.
The RNA-Based Therapeutics Market segmentation, based on Application, contains Genetic Disorders and Auto Immune Disorders. The genetic disorders category generated the most income, due to an increase in rare diseases, hereditary illnesses, and molecular diagnostics cases. These elements are anticipated to increase demand for RNA-based therapeutics.
Figure1: RNA-Based Therapeutics Market, by application, 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The RNA-Based Therapeutics Market segmentation, based on End User includes Research Institutes, and Hospitals & Clinics. The research institutes segment dominated the market, because of partnerships between academic research institutions and research organizations, or partnerships with government agencies to cover the high expense of research.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American RNA-Based Therapeutics market area will dominate this market. Due to the extensive infrastructure for research and development, the abundance of substantial research funds, and the expanding government activities towards RNA-based medicines, the market for RNA-based therapeutics is anticipated to grow.
Further, the major countries studied in the market report are US, Germany, France, UK, Canada, Italy, Spain, Australia, India, China, Japan, South Korea, and Brazil.
Figure2:RNA-BASED THERAPEUTICS MARKET SHARE BY REGION 2023 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Europe RNA-Based Therapeutics market owns the market's second-largest share due to the growing chronic illness prevalence and progress in RNA technologies. Further, the German RNA-Based Therapeutics market possessed the most market share, and the UK RNA-Based Therapeutics market was the market expanding at the fastest rate in Europe.
The Asia-Pacific RNA-Based Therapeutics Market is anticipated to expand between 2024 and 2032 at the quickest CAGR. This is due to boosting government funding and initiatives as well as partnerships and collaborations. Moreover, China’s RNA-Based Therapeutics market had the biggest market share, and the Indian RNA-Based Therapeutics market was the Asia-Pacific region's fastest-growing market.
RNA-Based Therapeutics Key Market Players& Competitive Insights
Leading market players are putting lot of money on R&D to expand their product categories, which will support the market's overall expansion for RNA-based therapies. Additionally, market players are engaging in a range of calculated initiatives to increase their worldwide presence, with important market developments involving the introduction of new products, contracts, M&A transactions, increased investment, and cooperation with other enterprises. To grow and endure in an increasingly cutthroat and dynamic market, RNA-Based Therapeutics industry must provide reasonably priced goods.
Manufacturing locally is one of the primary business techniques used by manufacturers to cut operational costs in the global RNA-Based Therapeutics industry to help customers and expand the market segment. In recent years, the RNA-Based Therapeutics industry has provided medicine with some of its biggest benefits. Major players in the RNA-Based Therapeutics market, including Arrowhead Pharmaceuticals, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Silence Therapeutics plc, Ionis Pharmaceuticals, Gradalis, Inc., and others, are engaging in research and development activities in an effort to boost market demand.
Arbutus Biopharma Corporation is a freely traded biopharmaceutical business based in Canada (NASDAQ: ABUS) that specializes in RNA interference and liposomal drug delivery. The company is currently working on creating medications to treat hepatitis B infection. The company's main office is in Warminster, Pennsylvania. Additionally, Inex had purchased personnel, manufacturing facilities and intellectual property licenses related to RNAi technology from Lynx Therapeutics in 1998; Tekmira was founded on these technologies, and its initial goal was to develop liposomally expressed RNAi drugs for a variety of indications. In July 2019, The RNA interference treatment ONPATTRO, which is being marketed by Alnylam Pharmaceuticals, has seen a portion of Arbutus Biopharma's royalty interest sold for $20 million to OMERS.
Biogen Inc. is headquartered in Cambridge, Massachusetts, and it works in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, the Netherlands, Poland, Sweden, and Switzerland. Gilbert and Sharp went on to win Nobel Prizes in Chemistry and Physiology or Medicine, respectively, in 1980 and 1993, respectively, for their understanding of DNA sequencing and the identification of split genes. In July 2020, Eisai and Biogen jointly declared that they had successfully applied for FDA research and marketing approval for Aducanumab.
Key Companies in the RNA-Based Therapeutics market include
RNA-Based Therapeutics Industry Developments
February 2023: Health Canada authorized Moderna, Inc. to market COVID-19 booster vaccine mRNA-1273.214 (SpikevaxBivalent Original/Omicron). This vaccination is intended to protect children and adolescents aged 6 to 17 from COVID-19.
January 2023: The US FDA designated Moderna's investigational mRNA vaccine candidate, mRNA-1345, as a breakthrough therapy. For individuals 60 years of age and above, this vaccine was created to protect against RSV-associated lower respiratory tract disease (RSV-LRTD).
September 2022: The European Commission authorized Alnylam Pharmaceuticals, Inc. to launch AMVUTTRA, an RNAi treatment. This therapy is intended for adult patients suffering with hereditary transthyretin-mediated polyneuropathy (hATTR) stage 1 or stage 2.
| Report Attribute/Metric | Details |
| Market Size2022 | USD 13.1 Billion |
| Market Size 2023 | USD 13.81 Billion |
| Market Size2032 | USD 22.32 Billion |
| Compound Annual Growth Rate (CAGR) | 6.10% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, End User, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | Australia, Germany, France, UK, Canada, Italy, Spain, South Korea, China, Japan, Brazil, Germany, France, India. |
| Key Companies Profiled | Â The following companies are in the list: Gradalis, Inc.; Silence Therapeutics plc; Arbutus Biopharma Corporation; Benitec Biopharma Inc.; and Arrowhead Pharmaceuticals. |
| Key Market Opportunities | ·      Greater advancements in the creation of therapies based on RNA aptamers |
| Key Market Dynamics | ·      Growing alliances and cooperative efforts between industry participants and producers of RNA technologies |
Frequently Asked Questions (FAQ) :
In 2022, the value of the global market for RNA-based therapeutics was estimated to be USD 13.1 billion.
From 2024 to 2032, The CAGR for the global market is predicted to be 6.10%.
North America held the most market share worldwide.
The following companies are in the list: Gradalis, Inc.; Silence Therapeutics plc; Arbutus Biopharma Corporation; Benitec Biopharma Inc.; and Arrowhead Pharmaceuticals.
In 2022, the market was dominated by the RNA Antisense category.
The global market share that Genetic Disorders held was the highest.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
